retatrutide patent eli lilly Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide

Lilly's triple agonist delivers up to 71.2 lbs of weight loss

27.47

★★★★☆4.8 (126)

Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market

20.46

★★★★★4.9 (98)

Eli Lilly's Phase 3 data is in on Retatrutide! Here's what they found:

21.30

★★★★★5.0 (157)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

27.90

★★★★★4.7 (84)

Eli Lilly wants to replace Zepbound with an even stronger weight loss drug

24.04

★★★★★4.9 (203)

Retatrutide, Eli Lilly's next generation of weight loss injections, showed dramatic results in clinical trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight

24.18

★★★★★5.0 (176)

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In

27.90

★★★★★4.8 (132)